Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH4 for Systemic Sclerosis Vasculopathy
NCT02530996Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2016
- Primary completion
- Jun 2016
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sapropterin in systemic sclerosis (SSc) (2 arms), sponsored by VA Office of Research & Development. Primary endpoints: Flow Mediated Dilatation - Diameter of Artery, Flow Mediated Dilatation - Shear Rate and 2 more. Started Jan 2016; status: completed.
02
Drugs
sapropterin
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02530996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530996.